MONUMENT-RE
Monument Re announced today that its Luxembourg subsidiary Monument Assurance Luxembourg S.A. (“MAL”) reached an agreement with Integrale Luxembourg to acquire its closed book portfolio of long term life insurance business. The portfolio serves mainly the Luxembourgish, Dutch and French markets, and is strategically aligned to MAL’s existing business model.
The portfolio and its employees will transfer into Monument’s Luxembourg operations upon receipt of all necessary regulatory approvals from the Bermuda Monetary Authority (“BMA”) and the Commissariat aux Assurances (“CAA”).
Monument Re Limited is a reinsurer and asset consolidator with a proven track record in the acquisition and operation of portfolios or direct insurers in Europe. Monument Re is present in Bermuda which, like Switzerland, is a fully Solvency II equivalent jurisdiction. The Monument Re Group operates through its subsidiaries in Belgium, Ireland, Isle of Man and Luxembourg, with branches in Guernsey, Spain, Italy, Germany and Singapore. Each entity is subject to local regulation and Monument Re is subject to Group Supervision by the Bermuda Monetary Authority.
Monument Assurance Luxembourg S.A. is a fully licensed Luxembourg life insurance company regulated by the Commissariat aux Assurances, with branches in Spain, Italy, and Germany. Its strategy is to acquire, by portfolio transfer or outright purchase, legacy guaranteed and linked portfolios in Luxembourg, Italy and Spain.
To learn more, please visit our website at www.monumentregroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005250/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MA-RENAGADE-THERAPEUTICS27.4.2024 02:10:34 CEST | Press release
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
NY-HCLTECH26.4.2024 22:07:31 CEST | Press release
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY
KINAXIS-INC.26.4.2024 18:04:28 CEST | Press release
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions
VERTEX-PHARMA26.4.2024 17:44:28 CEST | Press release
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
SUZANO-S.A.26.4.2024 17:23:27 CEST | Press release
Suzano 2023 annual report on Form 20-F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom